Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials
Schizophrenia is a severe, chronic and debilitating mental disorder. Past literature has reported various hypotheses about the psychopathology of schizophrenia. Recently, a growing literature has been trying to explain the role of inflammation in the etiopathogenesis of schizophrenia. In the past, n...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/3476240 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551681917714432 |
|---|---|
| author | Stefano Marini Domenico De Berardis Federica Vellante Rita Santacroce Laura Orsolini Alessandro Valchera Gabriella Girinelli Alessandro Carano Michele Fornaro Francesco Gambi Giovanni Martinotti Massimo Di Giannantonio |
| author_facet | Stefano Marini Domenico De Berardis Federica Vellante Rita Santacroce Laura Orsolini Alessandro Valchera Gabriella Girinelli Alessandro Carano Michele Fornaro Francesco Gambi Giovanni Martinotti Massimo Di Giannantonio |
| author_sort | Stefano Marini |
| collection | DOAJ |
| description | Schizophrenia is a severe, chronic and debilitating mental disorder. Past literature has reported various hypotheses about the psychopathology of schizophrenia. Recently, a growing literature has been trying to explain the role of inflammation in the etiopathogenesis of schizophrenia. In the past, numerous immune modulation and anti-inflammatory treatment options have been proposed for schizophrenia, but sometimes the results were inconsistent. Electronic search was carried out in November 2015. PubMed and Scopus databases have been used to find studies to introduce in this review. Only randomized-placebo-controlled add-on trials were taken into account. In this way, six articles were obtained for the discussion. Celecoxib showed beneficial effects mostly in early stages of schizophrenia. In chronic schizophrenia, the data are controversial, possibly in part for methodological reasons. |
| format | Article |
| id | doaj-art-7e87ec52b4674449970bd74d54bd23e7 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-7e87ec52b4674449970bd74d54bd23e72025-02-03T06:00:51ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/34762403476240Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsStefano Marini0Domenico De Berardis1Federica Vellante2Rita Santacroce3Laura Orsolini4Alessandro Valchera5Gabriella Girinelli6Alessandro Carano7Michele Fornaro8Francesco Gambi9Giovanni Martinotti10Massimo Di Giannantonio11Department of Neurosciences Clinical Imaging, Chair of Psychiatry, “G. d’Annunzio” University, 65100 Chieti, ItalyPolyedra Research Group, 64100 Teramo, ItalyDepartment of Neurosciences Clinical Imaging, Chair of Psychiatry, “G. d’Annunzio” University, 65100 Chieti, ItalyDepartment of Neurosciences Clinical Imaging, Chair of Psychiatry, “G. d’Annunzio” University, 65100 Chieti, ItalyPolyedra Research Group, 64100 Teramo, ItalyPolyedra Research Group, 64100 Teramo, ItalyPolyedra Research Group, 64100 Teramo, ItalyDepartment of Neurosciences Clinical Imaging, Chair of Psychiatry, “G. d’Annunzio” University, 65100 Chieti, ItalyNew York State Psychiatric Institute, Columbia University, New York, NY 10027, USADepartment of Neurosciences Clinical Imaging, Chair of Psychiatry, “G. d’Annunzio” University, 65100 Chieti, ItalyDepartment of Neurosciences Clinical Imaging, Chair of Psychiatry, “G. d’Annunzio” University, 65100 Chieti, ItalyDepartment of Neurosciences Clinical Imaging, Chair of Psychiatry, “G. d’Annunzio” University, 65100 Chieti, ItalySchizophrenia is a severe, chronic and debilitating mental disorder. Past literature has reported various hypotheses about the psychopathology of schizophrenia. Recently, a growing literature has been trying to explain the role of inflammation in the etiopathogenesis of schizophrenia. In the past, numerous immune modulation and anti-inflammatory treatment options have been proposed for schizophrenia, but sometimes the results were inconsistent. Electronic search was carried out in November 2015. PubMed and Scopus databases have been used to find studies to introduce in this review. Only randomized-placebo-controlled add-on trials were taken into account. In this way, six articles were obtained for the discussion. Celecoxib showed beneficial effects mostly in early stages of schizophrenia. In chronic schizophrenia, the data are controversial, possibly in part for methodological reasons.http://dx.doi.org/10.1155/2016/3476240 |
| spellingShingle | Stefano Marini Domenico De Berardis Federica Vellante Rita Santacroce Laura Orsolini Alessandro Valchera Gabriella Girinelli Alessandro Carano Michele Fornaro Francesco Gambi Giovanni Martinotti Massimo Di Giannantonio Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials Mediators of Inflammation |
| title | Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials |
| title_full | Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials |
| title_fullStr | Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials |
| title_full_unstemmed | Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials |
| title_short | Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials |
| title_sort | celecoxib adjunctive treatment to antipsychotics in schizophrenia a review of randomized clinical add on trials |
| url | http://dx.doi.org/10.1155/2016/3476240 |
| work_keys_str_mv | AT stefanomarini celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT domenicodeberardis celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT federicavellante celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT ritasantacroce celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT lauraorsolini celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT alessandrovalchera celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT gabriellagirinelli celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT alessandrocarano celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT michelefornaro celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT francescogambi celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT giovannimartinotti celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials AT massimodigiannantonio celecoxibadjunctivetreatmenttoantipsychoticsinschizophreniaareviewofrandomizedclinicaladdontrials |